Last reviewed · How we verify
Progesterone, micronized
At a glance
| Generic name | Progesterone, micronized |
|---|---|
| Also known as | Prometrium |
| Sponsor | Stanford University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. (PHASE4)
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- Luteal Support in Artificial Vitrified/Warmed Cycles With Low Progesterone (PHASE3)
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Exogenous Progesterone as Ovulation Trigger (PHASE4)
- A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix (PHASE3)
- Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Progesterone, micronized CI brief — competitive landscape report
- Progesterone, micronized updates RSS · CI watch RSS
- Stanford University portfolio CI